Brandon Scalea | Authors


Ibrutinib Maintenance Appears Safe in MCL Following Induction Therapy

June 25, 2019

Ibrutinib as a maintenance therapy for patients with mantle cell lymphoma who respond to frontline induction therapy with or without autologous stem cell transplant appeared safe and feasible, according to the results of a recent study presented at the 2019 ASCO Annual Meeting.

Dostarlimab Effective in Endometrial Cancer Regardless of MSI Status

May 28, 2019

Dostarlimab (TSR-042), an investigational anti–PD-1 therapy, demonstrated durable responses across subgroups of patients with microsatellite instability–high and microsatellite stable advanced or recurrent endometrial cancer, according to results from the phase I/II GARNET study.

CRC Field Moves Toward Unique, Tailored Approaches

May 02, 2019

Michael J. Overman, MD, discusses the combination regimen of nivolumab and ipilimumab in metastatic colorectal cancer and highlights existing challenges that still need to be addressed in future research.